Buradasınız

Anasayfa » Content

0.5% azithromycin gel as local drug delivery system in management of chronic periodontitis

Journal Name:

  • Indian Journal of Basic & Applied Medical Research

Publication Year:

  • 2013

Key Words:

Author Name
Abstract (2. Language): 
Introduction-Recent role of chemotherapeutic agents in form of local delivery system as an adjunct to mechanical therapy suggest improvement in periodontal health. The aim of present study was to evaluate clinical and microbiological effectiveness of locally delivered 0.5% azithromycin gel as an adjunct to scaling and root planing in managing chronic periodontitis patient. Material and Methods-This was randomized control trial using split mouth study design. A total of 40 sites from 20 patients, who had pocket depth more than 5 mm and diagnosed as chronic periodontitis, were selected for the study. These were randomly categorized in two treatment groups: scaling and root planning only (control group) and scaling and root planning plus 0.5% azithromycin gel (test group). Clinical parameters such as gingival index, probing pocket depth and clinical attachment level were recorded at baseline, 6 weeks and 12 weeks at selected sites for both the groups. Result & observations-Overall parameters improved from baseline in both test and control group. Mean pocket depth reduction from baseline to 12 weeks was 4.1500±0.6708 and 4.350±0.489 in test and control respectively, the difference being statistically significant at p<0.001.Mean clinical attachment level gain from baseline to 12 weeks, the difference being statistically significant at p<0.05. All microbiologic categories showed significant improvement in both groups, with greater improvement in the test group. Conclusion Based on the results it was concluded that locally delivered Azithromycin might be a valuable adjunct to scaling and root planing in the treatment of chronic periodontitis.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon 1121-1130.pdf.pdf
  • 8
1121-1130
  • English

REFERENCES

References: 

1. Haffajee AD, Socransky SS. Microbial and biological agents destructive periodontal diseases. Periodontol 2000
1994; 5: 78-11
2. Darveau P.R. Tanner,Page R.C.The microbial challenge in periodontitis.Periodontaol 2000;1997;14.12-32
3. Slots J, Rosling B. Suppression of the periodontopathic microflora in localized juvenile periodontitis by
systemic tetracycline. J Clin Periodontol 1983; 10: 465-86.
4. Van Winkelhoff AJ, Rams TE, Slots J. Systemic antibiotic therapy in periodontics. Periodontol 2000 1996; 10:
47-78.
5. Drisko CH. Non-surgical therapy: Pharmacotherapeutics. Ann Periodontol 1996; 1:491-518.
6. Position Paper. Systemic Antibiotics in Periodontics. J Periodontol
2004; 75: 1553-1565.
7. Goodson JM, Haffajee A, Socransky SS. Periodontal therapy by local
delivery of tetracycline; J Clin Periodontol 1979: 6 : 83 – 92
8. Rams T, Slots J: Local delivery of antimicrobial agents in the periodontal pocket. Periodontology 2000 1996;
10: 139-159.
Indian Journal of Basic & Applied Medical Research; September 2013: Issue-8, Vol.-2, P. 1121-1130
1129
www.ijbamr.com
9. Maizumi N, Tamura Y, Kanai H, Tsutsui T. Quantitative comparison of the cytocidal effect of seven macrolide
antibiotics on human periodontal ligament fibroblasts. J Periodont Res 2002; 37: 250-254.
10. Sefton AM, Maskell JP. Beighton D, Whiley A, Shain H, Foyle D, Smith SR. Smales FC, Williams JD.
Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol 1996; 23:
998-1003
11. Peters DH, Friedel HA, McTavish D. Azithromycin: A review of its antimicrobial activity, pharmacokinetic
properties and clinical efficacy. Drugs 1992;44:750-799.
12. Pajukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H. In vitro activity of azithromycin
compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents
Chemother 1992;36:1241-1243.
13. Pajukanta R. In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel
macrolide. Oral Microbiol Immunol 1993;8:325-326.
14. Filatova NA, Kuznetsov EA, Dmitrieva LA, Tsarev VN, Kalinin AI. The prospects for using the new macrolide
antibiotic azithromycin (Sumamed) in combined treatment of periodontitis (in Russian). Stomatologiia
(Mosk)1995;74:12-
15. Van Winkelhoff AJ, Herrera D, Winkel EG, Dellemijn- Kippuw N, Vandenbroucke-Grauls CM, Sanz M.
Antibiotic resistance in subgingival microflora in patients with adult periodontitis. A comparative survey
between Spain and the Netherlands (in Dutch). Ned Tijdschr Tandheelkd 1999;106:290-294
16. Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory
mediators in healthy human subjects. Eur J Pharmacol 2002;450:277-289.
17. Pajukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H. In vitro activity of azithromycin
compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents
Chemother 1992;36:1241-1243
18. Blandizzi C, Malizia T, Lupetti A, et al. Periodontal tissue disposition of azithromycin in patients affected by
chronic inflammatory periodontal diseases. J Periodontol 1999;70:960-966
19. Gomi K, Yashima A, Iino F, et al. Drug concentration in inflamed periodontal tissues after systemically
administered azithromycin. J Periodontol 2007;78:918-923.
20. Smith SR, Foyle DM, Daniels J, et al. A double-blind placebo-controlled trial of azithromycin as an adjunctto
non-surgical treatment of periodontitis in adults:Clinical results. J Clin Periodontol 2002;29:54-61.
21. Goodson JM, Offenbacher S, Fair DH and Hogan PE. Periodontal Disease Treatment by Local Drug Delivery; J
Periodonlogy 1985: 265 – 272
22. JW Krayer,RS Leite,KL Kirkwood; Dent Clin N Am 2010;54:13-33.
23. A.R. Pradeep, S.Vidya Sagar, and Happy Daisy,J Periodontol 2008;79:2125-35
24. Argani H, Pourabbas R, Hassanzadeh D, Masri M, Rahravi H.treatment of cyclosporine induced gingival
overgrowth with Azithromycin containing toothpaste. Exp Clin Transplant 2006; 4:420-424
25. Williams JD, Meskell JP, Shain H, et al. Comparative in vitro activity ofAzithromycin macrolides
(erythromycin, clarithromycin and spiramycin) andstreptogramin RP 59500 against oral organism. JAntimicrob
Chemother1992;30:27-37
26. Gomi K, Yashima A, Nagano T, Kanazashi M, Maeda N, Arai T. Effects of full mouth scaling and root planing
in conjunction with systemically administered azithromycin. J Periodontol 2007;78:422-429.

Thank you for copying data from http://www.arastirmax.com